New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$10.4m market cap, or US$7.06m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Board Change • Jan 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Dec 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.02m market cap, or US$4.66m). Ankündigung • Sep 30
Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025 Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025. New Risk • Sep 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$9.15m market cap, or US$6.05m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). New Risk • Aug 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$6.71m market cap, or US$4.35m). New Risk • Jul 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$4.80m market cap, or US$3.15m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). New Risk • Jan 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 29% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$18k revenue, or US$11k). Market cap is less than US$10m (AU$10.7m market cap, or US$6.65m). New Risk • Dec 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$18k revenue, or US$12k). Market cap is less than US$10m (AU$7.65m market cap, or US$4.87m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Ankündigung • Oct 04
Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024 Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024. New Risk • May 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 9.6% per year over the past 5 years. Revenue is less than US$1m (AU$168k revenue, or US$111k). Market cap is less than US$10m (AU$13.9m market cap, or US$9.19m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding). New Risk • Feb 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$97k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.22m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). New Risk • Dec 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$98k). Market cap is less than US$10m (AU$12.1m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Ankündigung • Nov 23
Bio-Gene Technology Limited Approves the Election of Alex Ding as Director Bio-Gene Technology Limited at its AGM held on November 23, 2023, approved the election of Mr. Alex Ding as a Director. Ankündigung • Oct 30
Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary Bio-Gene Technology Limited announced the appointment of Mr. Roger McPherson as joint Company Secretary on an interim basis. Roger has more than 25 years' experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. In the past, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio- Gene, Patrys Limited, TPI Enterprises Ltd. and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 20 years of biotechnology and pharmaceutical experience. In addition to his role with Bio-Gene, Roger also provides CFO services to other unlisted entities. Ankündigung • Oct 02
Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023 Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time. New Risk • Sep 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$95k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (AU$17.6m market cap, or US$11.2m). New Risk • Aug 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$681k revenue, or US$450k). Market cap is less than US$10m (AU$15.1m market cap, or US$10.00m). Reported Earnings • Aug 01
Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022) Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022). New Risk • Jun 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.6% per year over the past 5 years. Revenue is less than US$1m (AU$97k revenue, or US$65k). Market cap is less than US$10m (AU$14.3m market cap, or US$9.58m). Ankündigung • May 12
Bio-Gene Technology Limited Announces Changes to the Board Bio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy. He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness. Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022) First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Ankündigung • Dec 01
Bio-Gene Technology Limited Submits Application to Secure Additional IP for Qcidetm Bio-Gene Technology Limited announced the filing of an application for PBR of several Eucalyptus cloeziana varieties containing high levels of tasmanone - the insecticidal ingredient in Qcide oil. This is an important milestone in Bio-Gene's Qcide tree improvement program which will significantly add to the value of the Company's technology. The extended period offered by these rights provides protection for the genetic material which improves both the yield and quality of Qcide oil, which translates to advantages for its commercial collaborators as they develop new and novel products for the marketplace. The ongoing development of IP for the company's technology platform is a key component of the company's strategic plan to deliver value to its customers and shareholders. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 30
Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022 Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022, at 11:00 AUS Eastern Standard Time. Reported Earnings • Aug 18
Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021) Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Mar 07
Bio-Gene Technology Limited Announces Positive Stored Grain Pest Results Bio-Gene Technology Limited announced positive results from the latest stored grain trial, showing efficacy over the targeted 9-month protection period. In September 2020, Bio-Gene announced the successful identification of a lead Flavocide combination treatment to be taken to field testing as part of a 9-month efficacy study in collaboration with its research and commercial partners. The 9-month combination treatment study is stage 3 of the collaboration program. This stage of the program was designed to demonstrate the effectiveness of the combination treatment to control five of the key stored grain pests, being the Lesser grain borer, Flour beetle, Saw-toothed grain beetle, Flat grain beetle and Rice weevil. The 3-month interim results were announced during 2021 and showed that the combination treatments were providing control of all of five key pests at this intermediate stage. Assessments were subsequently undertaken at 6 and 9 months after treatment. Results showed that the combination treatments provided complete control of non-resistant strains of all species, as well as control of resistant strains of three of the five target species, for the full 9-month testing period. Resistant strains of two of the five target species were controlled for a 3-month period, indicating that higher rates of application or alternative combination treatments would be required to control these highly resistant strains for a longer period. The Department of Agriculture and Fisheries, Queensland (DAF) also recently reported on testing of Flavocide against Lesser grain borer in other grain types namely maize and barley. The results showed that Flavocide provided similar levels of control to that obtained in wheat. Currently there is no single chemistry that controls all major pests that impact stored grain. The incidence of pest resistance is rising in Australia, and around the world. In some cases, losses of up to 70% of grain in storage have been attributed to pests1. Flavocide has the potential to create formulations that will enable control of the full range of pests including pests resistant to other classes of chemistry. The introduction of products with a novel Mode of Action, such as Flavocide, is critical for pest management in stored grain to reduce the potential of increased insecticide resistance in the future. Reported Earnings • Feb 21
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Earnings per share (EPS) exceeded analyst estimates by 75%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 07
Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory Affairs Bio-Gene Technology Limited announced the appointment of Sarah Driessens to the role of Head of Regulatory Affairs with global responsibilities. Sarah has recently relocated to Australia, after previously being based in Brussels, Belgium. Sarah has worked for over 13 years with Monsanto. Her main areas of focus were product registration for agricultural and consumer products across major geographic jurisdictions. Sarah will commence with Bio-Gene in late February 2022. Ankündigung • Dec 17
Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in funding On December 17, 2021, Bio-Gene Technology Limited closed the transaction. The company has amended the terms of the transaction. The company has issued 17,927,941 fully paid shares at a price of AUD 0.17 per share for the gross proceeds of AUD 3,047,750. The company issued shares without disclosure to investors under Part 6D.2 of the Act. Ankündigung • Dec 09
Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in funding Bio-Gene Technology Limited announced a private placement of 18,937,119 common shares at a price of AUD 0.17 per share for the gross proceeds of AUD 3,200,000 on December 9, 2021. The transaction will include participation from directors of the company, new and existing sophisticated and professional investors. The transaction is subject to approval to Shareholder Approval. The transaction is expected to be closed by December 19, 2021. Reported Earnings • Aug 27
Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020) Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Breakeven Date Change • Jul 04
Forecast to breakeven in 2024 The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule. Ankündigung • Feb 25
Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021 Bio-Gene Technology Limited announced the appointment of Mr. James Joughin as a Non-executive Director of the Company and Chairman of Audit and Risk Committee. James is a highly experienced ASX listed and private company Director. He is currently the Non-Executive Chairman at Spirit Technology Solutions Ltd. and a Non-Executive Director at Mydeal.com.au Ltd, Viridian Financial Group Ltd. and Melbourne Institute of Technology Pty Ltd. Mr. Joughin's appointment is effective from 1 March 2021. Ankündigung • Feb 24
Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of Activity Bio-Gene Technology Limited announced the successful completion of additional mode of action ("MoA") studies which confirm a definitive target site of Flavocide in insects. These results represent a key milestone in the development of Bio-Gene's proprietary insecticide technology. Previous studies demonstrated that Flavocide has a MoA quite different to other known insecticide classes, with activity located within a region of the insect not targeted by other chemistry. These results were supported by testing on populations of pests resistant to other classes of chemistry, where Bio-Gene's technology was shown to control those pests. This provided Bio-Gene with a candidate target site within insects with which to conduct these
more definitive studies. This latest series of studies undertaken by the specialist contract research company Pacific Discovery Services - sought to identify a definitive target site using more advanced and directed methodology. This testing resulted in a response to Flavocide that was identical to that found in previous studies but was more clearly expressed, therefore confirming this as a definitive target site of Flavocide. Categorically identifying the site of the unique MoA for Flavocide and QcideTM will enable increased engagement with both industry experts and commercial companies who are looking to find new chemistry to develop effective commercial products. These results also provide critical information that will be important in creating validation data which will ultimately enable Bio-Gene to apply for a "new class of chemistry" with IRAC (Insecticide Resistance Action Committee), a specialist technical group of the global industry association CropLife. A unique classification means Flavocide, and other beta-triketone-based insecticides such as Bio-Gene's Qcide, would be incorporated into current and future Resistance Management Programs developed by the industry for specific pest/crop situations. Reported Earnings • Feb 20
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020) First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Ankündigung • Jan 22
Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity Studies Bio-Gene Technology Limited announced positive preliminary results from aquatic (Rainbow Trout) and avian (Mallard Duck) eco-toxicity studies. These studies were undertaken with technical grade flavesone, the active constituent contained in Flavocide, and contribute strongly to the data package that will support regulatory approval and commercialisation. This most recent study was performed on Rainbow Trout (Oncorhynchus mykiss) under the Organisation for Economic Co-Operation and Development guidelines for fish acute toxicity testing. The results of the study indicated that based on a five-step scale used to classify pesticides into toxicity categories for terrestrial and aquatic organisms, Flavocide was classed as `practically non-toxic' and therefore falls within the lowest toxicity category for this species. The study represents a continuation of the recent testing of Flavocide on other non-target species in aquatic eco-systems announced in June 2020 that included data on Poecilia reticulata (Guppy), Daphnia magna (water flea) and Pseudokirchneriella subcapitata (freshwater algae). Overall results showed that no adverse effects were observed in any species from exposure to Flavocide at the doses tested, which included the highest doses able to be achieved within the limitation of water solubility of the compound. Rainbow Trout is a key target temperate species used to indicate the environmental impact from the use of a pesticide in an aquatic environment. Acute toxicity studies are key to further profiling and understanding the potential hazards posed by products containing flavesone when released into the environment, with particular relevance to outdoor uses such as for mosquito control and crop protection. Mallard Duck (Anas platyrhynchos) represents a key aquatic avian species to assess the impact from the introduction of an insecticide to the environment. This study positively builds on the previous study undertaken on a land-based avian species (Japanese Quail) and aims to further profile the effects of Flavocide on different avian species that occupy both terrestrial and aquatic habitats. These studies compliment the aquatic species studies and are also pivotal to further profiling and understanding the safety profile of products containing flavesone when released into the environment. The studies involved administering Flavocide to birds at a range of dose levels to accurately determine the acute oral toxicity effects. Based on a five-step scale used to classify pesticides into toxicity categories for terrestrial and aquatic organisms, the trial determined Flavocide technical was `moderately toxic' and therefore falls into the middle toxicity category for this species. A moderately toxic classification is well within the range of currently registered insecticides and thus a positive outcome in terms of expected non-target impact assessment for registration. These preliminary data on Rainbow Trout and Mallard Duck, together with eco-toxicity data recently obtained on other non-target species, would indicate that Flavocide would likely have minimal impact on non-target species in both aquatic and terrestrial eco-systems. These results continue to provide evidence to support a strong safety profile for products containing Flavocide which may inadvertently encounter non-target species in the environment. Most importantly, the information will also aid product registrations and support promotion of Bio-Gene products to potential commercial partners with an interest in commercialising the company's technology and products. Ankündigung • Dec 19
Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020 Bio-Gene Technology Limited announced the appointment of Dr. Peter Beetham as a Non- executive Director of the Company. Dr. Beetham is the co-founder and Chief Executive Officer of Cibus Global, LLC (Cibus). Dr. Beetham's appointment is effective from 21 December 2020. Dr. Beetham has over 30 years of experience in the bio-agriculture community, with a passion for moving
technology to commercial application. He was employed by the Victorian Department of Agriculture and Rural Affairs (DARA) in Australia from 1985 to 1992, serving as a Scientific Officer based at the Plant Research Institute (PRI), working with research groups throughout Southeast Asia and the South Pacific. Ankündigung • Nov 26
Bio-Gene Technology Limited Announces Changes of Directors Bio-Gene Technology Limited announced in the Results of Meeting, Non-executive Chairman Don Brumley and Non-executive Director Kevin Rumble were not re-elected by shareholders at the 2020 Annual General Meeting (AGM) and have therefore retired as Directors of the Company effective at the close of the 2020 AGM. The Board is, and has been, on a path to make some changes that will result in the company benefitting from additional non-executive expertise. The Company is currently progressing discussions and the due diligence process with several potential candidates. Don, who led the Company to and through the IPO process and Kevin, whose passion as the founder of the Company has strongly supported the progress achieved to date. The remaining Directors have also resolved that Non-executive Director Robert Klupacs will act as the Company's Chairman in an interim capacity until the process of appointing new non-executive directors is concluded. The Company will make further announcements in that regard in due course. Ankündigung • Jun 19
Bio-Gene Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.427998 million. Bio-Gene Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.427998 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,761,276
Price\Range: AUD 0.155